Psychological interventions for enhancing adherence to disease-modifying therapies (DMTs) in multiple sclerosis by Csillik, A. et al.
Cochrane Database of Systematic Reviews
Psychological interventions for enhancing adherence to
disease-modifying therapies (DMTs) in multiple sclerosis
(Protocol)
Csillik A, Bruce J, Catley D, Gay MC, Goggin KJ, Swaggart KR, Thomas PW, Thomas S
Csillik A, Bruce J, Catley D, Gay MC, Goggin KJ, Swaggart KR, Thomas PW, Thomas S.
Psychological interventions for enhancing adherence to disease-modifying therapies (DMTs) in multiple sclerosis.
Cochrane Database of Systematic Reviews 2016, Issue 11. Art. No.: CD012443.
DOI: 10.1002/14651858.CD012443.
www.cochranelibrary.com
Psychological interventions for enhancing adherence to disease-modifying therapies (DMTs) in multiple sclerosis (Protocol)
Copyright © 2016 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
T A B L E O F C O N T E N T S
1HEADER . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
1ABSTRACT . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
1BACKGROUND . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
3OBJECTIVES . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
3METHODS . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
7ACKNOWLEDGEMENTS . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
7REFERENCES . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
10APPENDICES . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
10CONTRIBUTIONS OF AUTHORS . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
11DECLARATIONS OF INTEREST . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
iPsychological interventions for enhancing adherence to disease-modifying therapies (DMTs) in multiple sclerosis (Protocol)
Copyright © 2016 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
[Intervention Protocol]
Psychological interventions for enhancing adherence to
disease-modifying therapies (DMTs) in multiple sclerosis
Antonia Csillik1, Jared Bruce2, Delwyn Catley3, Marie-Claire Gay1, Kathleen J Goggin4 , Keri R Swaggart5, Peter W Thomas6, Sarah
Thomas6
1Department of Psychology, University of Paris Ouest Nanterre, Nanterre La Dèfense Cedex, France. 2Department of Psychology,
University of Missouri-Kansas City, Kansas City, Missouri, USA. 3Children’s Mercy Hospital & University of Missouri-Kansas City,
Kansas City, MO, USA. 4Health Services and Outcomes Research & Schools of Medicine and Pharmacy, Children’s Mercy Hospital
& University of Missouri, Kansas City, MO, USA. 5Library Services, The Children’s Mercy Hospital and Clinics, Kansas City, MO,
USA. 6Bournemouth University, Clinical Research Unit, Faculty of Health and Social Sciences, School of Health and Social Care,
Bournemouth University, Bournemouth, UK
Contact address: Antonia Csillik, Department of Psychology, University of Paris Ouest Nanterre, 200, Avenue de la République,
Nanterre La Dèfense Cedex, F-92001, France. acsillik@u-paris10.fr, ascillik@yahoo.fr.
Editorial group: Cochrane Multiple Sclerosis and Rare Diseases of the CNS Group.
Publication status and date: New, published in Issue 11, 2016.
Citation: Csillik A, Bruce J, Catley D, Gay MC, Goggin KJ, Swaggart KR, Thomas PW, Thomas S. Psychological interventions for
enhancing adherence to disease-modifying therapies (DMTs) in multiple sclerosis. Cochrane Database of Systematic Reviews 2016, Issue
11. Art. No.: CD012443. DOI: 10.1002/14651858.CD012443.
Copyright © 2016 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
A B S T R A C T
This is a protocol for a Cochrane Review (Intervention). The objectives are as follows:
To assess the effects of psychological interventions designed to improve adherence to disease-modifying therapies (DMTs) in adults
with multiple sclerosis (MS) in terms of adherence. This will be considered in relation to levels of adherence in a comparison group.
Secondary objectives are to assess the impact of interventions on potential predictors of adherence such as motivation, self-efficacy
beliefs and healthcare engagement to DMTs adherence.
B A C K G R O U N D
Description of the condition
Among the autoimmune diseases of the central nervous system
(CNS), multiple sclerosis (MS) is the most common inflamma-
tory neurologic disease among young and middle-aged adults. MS
is caused by a complex array of genetic and environmental factors
that contribute to an increased prevalence among females born
in temperate climates (Courtney 2009). Patients typically present
with a relapsing-remitting course of the disease that is characterised
by periodic exacerbations, followed by recovery and stretches of
relative stability (Lublin 1996). Eventually, most patients convert
to a secondary progressive course that is characterised by a gradual
accumulation of disability (Confavreux 2006). Lifespan is mini-
mally impacted in MS; however, the disease contributes to physi-
cal, emotional, and cognitive symptoms that substantially reduce
participants’ overall quality of life (Amato 2001; Benedict 2005).
Although there is no cure for MS, several disease-modifying ther-
apies (DMTs) have been shown to reduce the number and severity
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of exacerbations, as well as slow disease progression and improve
quality of life (Castro-Borrero 2012; Kieseier 2008). DMTs repre-
sent a broad class of drugs that are designed to alter immune system
functioning, reduce the occurrence ofMS relapses and slowdisease
progression. Different therapies are available for the treatment of
multiple sclerosis including immunosuppressants, immunomod-
ulators, and monoclonal antibodies. The benefits of therapy are
preventive and not directly observed by patients. Randomised tri-
als show that DMTs contribute to a 33% to 68% reduction in
relapse rates, a 35% to 83% reduction in new central nervous sys-
tem lesion activity, and up to a 50% reduction in disability pro-
gression (Bosch-Capblanch 2007; Freedman 2008; Goodin 2008;
Johnson 2009; Linker 2008). A recent study show that DMTs sig-
nificantly decreased new cortical lesion development and cortical
atrophy progression compared with untreated patients, with faster
and more pronounced effects seen with subcutaneous interferon
(IFN) beta-1a than with intramuscular IFN beta-1a or glatiramer
acetate (GA) (Calabrese 2012). Absolute risk reductions for MS
exacerbations range from 11% to 43% with the average number
of patients needed to treat to prevent one exacerbation ranging
from two to nine (Zakaria 2015).
Natalizumab and IFNß-1 are superior to all other treatments
for preventing clinical relapses and disability progression in the
short term (24 months) in people with relapsing-remitting MS
(RRMS). The IFNß-1b (Betaseron), GA, and mitoxantrone are
also effective, with moderate-quality data, for preventing relapse
and disability progression in RRMS in the short term (Filippini
2013). Another recent Cochrane review assessing the benefits and
the extent of adverse events associated with 15 disease-modifying
drugs showed that alemtuzumab, natalizumab, and fingolimod are
more effective than other drugs for preventing relapses (Tramacere
2015). For preventing irreversible disability worsening in the short
term (24 months), only natalizumab shows a beneficial effect on
the basis of moderate-quality evidence. Despite evidence of effi-
cacy for natalizumab, participants must also confront the possi-
bility of more severe adverse events (SAE), including the risk of
death due to progressive multifocal leukoencephalopathy (PML).
Other SAE including thrombosis of the jugular vein and aller-
gic reactions leading to treatment discontinuation were found in
some studies. However, the treatments for which information on
SAEs were available included in this review were associated with
a statistically non-significant higher proportion of people with at
least one SAE compared with placebo (Tramacere 2015).
Unfortunately, typical of many chronic diseases, a near majority
of people with MS may not receive the benefits of the DMTs
due to poor adherence (Bruce 2011), which can take many forms.
People with MS may disregard their healthcare providers’ recom-
mendations, discontinue treatments prematurely, miss doses, or
have difficulty following treatment instructions. Several actuarial
research studies suggest that between 30% and 50 % of people
withMS prematurely discontinue theirDMTs (Giovannoni 2012;
Reynolds 2010; Tan 2011;Wong 2011). Moreover, among people
who continue to take DMTs, a fifth may miss more than 20%
of their prescribed doses (Bruce 2010a). As a result, these people
have an increased risk of experiencing exacerbations, new brain
lesions, and worsening disability (Freedman 2008).
Relatively little research has examined factors that contribute to
poor DMT adherence in MS, but researchers have argued that
people with MS and others with chronic illness may be at espe-
cially high risk of premature treatment discontinuation and poor
long-term adherence because treatments do not typically reduce
acute symptoms (Bruce 2011). Thus, while people with MS are
less likely to develop future symptoms when on medication, they
do not experience any improvements in their daily activities while
on themedications. In fact, frequently, they experience side-effects
from themedications, andmay therefore feel they are experiencing
a reduction in quality of life without any apparent benefit. Side-
effects such as stomach upset, flu-like symptoms, injection site
reactions can make adherence challenging and almost all of the
drugs included in a recent Cochrane review were associated with
a higher proportion of participants who withdrew due to adverse
events compared to placebo (Tramacere 2015). Studies of discon-
tinuation and adherence maintenance have found that DMT side-
effects and perceived lack of DMT efficacy are among the most
consistent predictors of adherence in MS (Jokubaitis 2013; Rinon
2011; Turner 2007). Complacency has also been evident among
people who have reported being “too busy” to adhere (Bruce 2011;
Devonshire 2011; Hancock 2011). Other barriers that have been
shown to be associated with poor adherence include medication
costs, lack of provider support, and neuropsychiatric disability (in-
cluding negative affect, fatigue, cognitive impairment, and needle
phobia) (Bruce 2010a; Bruce 2010b; Koudriavtseva 2012; Mohr
1999; Patti 2010; Rinon 2011).
The fact that patients frequently discontinue treatments suggests
that there is patient dissatisfaction with current DMTs. Indeed,
the frequent use of complementary and alternative medicines (by
an estimated 57% to 70% of patients with MS) also supports the
view that conventional therapies are not adequately meeting pa-
tient needs (Giovannoni 2012; Nayak 2003; Page 2003). Indeed,
there are reasonable motives for some people to decline the use of
DMTs. With the increased availability of various evidence-based
treatments, it is important that people have access to adequate
information in order to make informed choices and minimise the
possible negative effects of treatment. In this context, it is imper-
ative to evaluate which strategies are most effective to enhance
informed choice and subsequent adherence (Foster 2012; Köpke
2014; Stacey 2014).
Description of the intervention
Adherence interventions typically use educational, psychological
and/or behavioural techniques to help people follow agreed-upon
treatment recommendations. A variety of different strategies have
been suggested for improving adherence in MS, including struc-
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tured education programs, regular nurse assistance, and psycho-
logical interventions (Berger 2005; Nieuwlaat 2014). These inter-
ventions are designed to help people overcome common barriers
to poor adherence and typically include face-to-face, individual or
group therapy, telephone, or web-based contacts. Easthal’s meta-
analysis (Easthall 2013), showed that cognitive-based behaviour
change techniques are effective interventions in eliciting improve-
ments in medication adherence and are likely to be greater than
the behavioural and educational interventions largely used in cur-
rent practice. Evidence is limited on whether these approaches are
broadly applicable or affect long-term medication adherence and
health outcomes (Viswanathan 2012).
Adherence interventions are usually multi-modal or ‘complex’
(Craig 2008), in that they include several components that may
or may not interact. These could incorporate a combination of
educational, psychological and behavioural techniques to support
people with MS to follow agreed-upon treatment recommenda-
tions. Our focus in this review is whether these complex inter-
ventions work in their entirety but, we will extract detailed de-
scriptions (where available) of the individual intervention compo-
nents and process and contextual factors in line with guidance for
the description and reporting of trials of complex interventions
(Hoffman 2014; Möhler 2012).
We will include interventions mostly, or wholly, based on psycho-
logical theories and practice, which aim to improve adherence to
DMTs. Experimental interventions will include those focusing on
initiation of a DMT for the first time and those which are re-ini-
tiating a DMT, as well as increasing the percentage of prescribed
doses taken, in those already taking a DMT. We will include all
kinds of strategies and all modalities to deliver them.
The comparison group could include standard treatment, no inter-
vention, placebo treatment or another active intervention aimed to
increase adherence toDMTs. Standard treatment varies across sites
and countries; it usually consists of basic education about symptom
management, information and support, options for pharmaco-
logic and nonpharmacologic management, family issues, instruc-
tion for self-administration, and information on the incidence and
management of side-effects. We will consider all modalities to de-
liver them.
How the intervention might work
The focus of this review is on psychological interventions that aim
to improve adherence directly by increasing participants’ motiva-
tion to adhere to recommendations to take DMT. Motivational
interventions may attempt to enhance the perceived importance
and benefits of DMT and address potential barriers. In addition,
the interventions may work by providing education and increasing
participants’ self-efficacy and skills to use treatment as prescribed.
We will also consider interventions that directly or indirectly in-
crease adherence to DMTs such as cognitive-behavioural inter-
ventions to teach anxiety-reduction skills, challenge phobic anxi-
ety through exposure, and address maladaptive thoughts through
cognitive restructuring. A combination of these approaches may
improve adherence by both increasing patient motivation and of-
fering supports that help people overcome barriers to change.
Why it is important to do this review
Adherence to DMTs is essential to maximise treatment benefit
and to ensure the cost-effectiveness of treatments. Enhancing ad-
herence has the potential to lead to improved health outcomes
among people with MS. Little is known ab)out the types or effi-
cacy of adherence interventions that have been used in MS. No
published systematic reviews address this specific question to date.
A Cochrane Review (Nieuwlaat 2014) assessed the results of ran-
domised controlled trials (RCTs) of interventions to help people
adhere to prescribed medications, however adherence to DMT
treatments by people with MS is not addressed in this review and
it does not focus specifically on psychological interventions.
O B J E C T I V E S
To assess the effects of psychological interventions designed to im-
prove adherence to disease-modifying therapies (DMTs) in adults
with multiple sclerosis (MS) in terms of adherence. This will be
considered in relation to levels of adherence in a comparison group.
Secondary objectives are to assess the impact of interventions on
potential predictors of adherence such as motivation, self-efficacy
beliefs and healthcare engagement to DMTs adherence.
M E T H O D S
Criteria for considering studies for this review
Types of studies
We will include randomised controlled trials (RCTs) and cluster-
RCTs in which a psychological intervention addressing adherence
to DMT in adults is compared to standard treatment, no treat-
ment/placebo treatment or another active intervention and where
adherence is assessed. We will not consider a follow-up period as
an exclusion criterion. Cross-over trials will also be included.
Types of participants
Wewill include adults (18 years and over) diagnosed with all types
of clinically definite MS (regardless of psychiatric comorbidities
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or level of disability) and clinically Isolated syndrome (CIS), de-
fined according to the Poser (Poser 1983) and revised McDonald
(McDonald 2001; Polman 2005; Polman 2011) criteria. The re-
vised McDonald criteria for MS diagnosis will be applied when
people have experienced a typical CIS (or progressive parapare-
sis/cerebellar/cognitive syndrome in the case of suspected primary
progressive MS (PPMS). Participants could include those starting
on any form of DMT for the first time or those who are re-ini-
tiating a DMT, regardless of the amount of prior use of therapy.
Studies that include people with MS and people with other health
conditions will be excluded unless the results for people with MS
have been presented separately.
Types of interventions
We will include interventions, mostly or wholly based on psycho-
logical theories and practice, which aim to improve adherence to
DMTs versus standard treatment, no intervention, placebo treat-
ment or another intervention. Interventions could include those
focusing on initiation of a DMT for the first time and those who
are re-initiating a DMT, as well as improving adherence amongst
those already taking DMTs. Interventions can address patients,
providers and care givers.
Types of outcome measures
Primary outcomes
The primary outcome of the review will be adherence to DMTs;
adherence will be evaluated in terms of percentage of:
• percentage of doses taken;
• percentage above a threshold of number of doses;
• proportion of participants starting DMT;
• proportion of participants stopping medication; and
• others used in the literature on adherence to DMTs in
people with MS.
Wewill examine short-term (less than threemonths after randomi-
sation) and long-term (greater than three months after randomisa-
tion) outcomes separately. We will include studies with a measure
of adherence regardless if it is a primary or secondary outcome in
the studies.
Secondary outcomes
We will also include outcomes related to :
• motivation to adhere;
• self-efficacy to adhere; and
• healthcare engagement (e.g. attending a neurology
appointment to discuss re-initiation of DMTs).
We will include adverse effects of the adherence interventions such
as increased anxiety or needle pricks/infections in the context of
needle phobia interventions (but not adverse effects of the DMT
treatments themselves as this is not the focus of the current review).
Search methods for identification of studies
Electronic searches
The Information Specialist will search the Trials Register of the
CochraneMultiple Sclerosis and Rare Diseases of theCNSGroup,
which, among other sources, contains trials from:
• Cochrane Central Register of Controlled Trials
(CENTRAL) (2016, most recent issue);
• MEDLINE (PubMed) (1966 to date);
• Embase (Embase.com) (1974 to date);
• Cumulative Index to Nursing and Allied Health Literature
(CINAHL) (EBSCOhost) (1981 to date);
• Latin American and Caribbean Health Science Information
Database (LILACS) (Bireme) (1982 to date);
• ClinicalTrials.gov (http://clinicaltrials.gov); and
• World Health Organization (WHO) International Clinical
Trials Registry Platform (apps.who.int/trialsearch).
Information on the Group’s Trials Register and details of search
strategies used to identify trials can be found in the ’Specialised
Register’ section within the Cochrane Multiple Sclerosis and Rare
Diseases of the Central Nervous System Group’s module.
The keywords that we will use to search for trials for this review
are listed in Appendix 1.
Searching other resources
In addition we will:
• screen reference lists and published reviews for additional
trials;
• search dissertations and theses from System for Information
on grey Literature in Europe (Single) and conference
proceedings, congress abstracts, reports, professional society
meetings and websites of the main MS associations;
• contact researchers working on this topic and especially lead
authors of identified trials to identify studies;
• Search for meeting abstracts from MS associations to
identify other published or unpublished peer-reviewed trials.
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Data collection and analysis
Selection of studies
We will assess studies according to the methods highlighted
in theCochrane Handbook for Systematic Reviews of Interventions
(Higgins 2011a). Two review authors, one a content expert (AC,
MCG), will independently screen titles and abstracts identified
from the search for their relevance for inclusion in the review. Stud-
ies will be reviewed for relevance based on study design, types of
participants and interventions. The full-text publications of those
deemed either eligible or potentially eligible will be obtained as
well are for those where it is unclear. We will identify and exclude
duplicates and will collate multiple reports of the same study so
that each study is the unit of interest rather than reports. The
two review authors will independently screen the full-text publi-
cations and identify studies for inclusion in the review according
to the predetermined eligibility criteria. Eligibility criteria will be
assessed in a prespecified order. Reasons for exclusion of studies
will be recorded in the table ‘Characteristics of excluded studies’.
Disagreements about whether a study should be included will be
resolved by discussion among the two review authors (AC, MCG)
and, if necessary, a third review author (KG) will be consulted to
arbitrate.
Review authors will not be masked to the name(s) of the author(s)
institution(s) or publication source at any level of the review.
Data extraction and management
Data extraction will be undertaken by a content expert and a
methodologist (JB, PWT). We will design a data extraction form.
Data will be extracted independently using the bespoke form. We
will extract the following information from the included studies.
• Date, country and clinical setting of trial.
• Study design.
• Rationale: aim of the intervention (e.g. DMT initiation or
re-initiation, or both).
• Eligibility criteria.
• Participant characteristics (e.g. age, gender, years since
diagnosis, type of MS, degree of disability, psychiatric diagnosis).
• Description of intervention (intent (e.g. reduce needle
phobia, increase confidence etc.) duration, frequency, how
delivered, who delivered, format of delivery, training of person
delivering, whether adapted for MS, whether concomitant
interventions were given).
• Type of comparison group(s) and, if appropriate,
description of the duration, frequency, how delivered, who
delivered, format of delivery, training of person delivering,
whether adapted for MS, and whether concomitant
interventions were given.
• Comparability of baseline characteristics between treatment
and control groups.
• Description of follow-up.
• Outcomes measured, whether primary or secondary, and
when they were recorded.
• Number enrolled in trial and in each group.
• Presence of sample size calculation.
• Numbers included at each follow-up in each group.
• Attempts at masking.
• Description of randomisation and allocation concealment.
• Intention-to-treat principle - whether participants were
analysed in the group to which they were originally assigned,
number and reasons for dropout and withdrawal in each group,
and missing data assumptions used in the analysis. If data have
been analysed separately using both intention-to-treat and per
protocol approaches, preference will be given to the former.
• For nominal outcomes (denominator and numerator in
each category for each group).
• For interval and ordinal data (N, mean, standard deviation
(SD) for each group) or (N, median, interquartile range (IQR)
or range) as appropriate.
• Notes: funding source and any potential conflicts of interest
for the authors.
Once data have been extracted, descriptive information on clin-
ical populations, interventions and outcomes will be passed to
the Clinical Heterogeneity Group to review. This review will be
undertaken blinded to study results. The Clinical Heterogeneity
Group will decide which studies are similar enough in clinical
and methodological content for combination in a meta-analysis
to make sense, and will consist of three revIew authors members
of the team (ST, DC, AC) with expertise in psychological inter-
ventions.
We will include studies reported as full text, those published as
abstract only, and unpublished data. We will contact Chief Inves-
tigators to provide additional (unpublished) relevant information
if necessary. One review author (PT) will enter the extracted data
into RevMan software (Review Manager 2015) and a second re-
view author (ST) will cross-check the data entry.
All studies that meet the inclusion criteria will be summarised in
the ’Characteristics of included studies’ table provided in RevMan
software (ReviewManager 2015) developed by Cochrane and will
include details related to design, participants, interventions and
outcomes
Assessment of risk of bias in included studies
Two review authors (AC, ST) will independently assess the risk
of bias in included studies with any disagreements resolved by
discussion or arbitration by a third review author (PT). The risk
assessment for each included study will be presented in the ’Risk
of bias’ table. We will contact the study authors for additional
information about the study methods as necessary.
Two review authors (ST, PWT) will assess the included articles
(without masking of source and authorship) for study quality us-
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ing Cochrane’s tool for assessing risk of bias Chapter 8 (Higgins
2011b) that encompasses the following domains: random se-
quence generation, allocation concealment, masking of partici-
pants and personnel, blinding of outcome assessments, incom-
plete outcome data, selective reporting and ‘other’ sources of bias.
A judgment of yes indicates a low risk of bias, no a high risk of
bias and unclear either unclear or unknown risk of bias. However,
masking patients and clinicians to treatment allocation is typically
not possible in trials of psychological interventions. For this do-
main, our assessment of blinding will include only the outcome
assessors (i.e. it will not include participant-reported outcomes).
We will also consider whether the intervention was standardised
and the validity and reliability of outcome measures. For each
study and for each outcome, risk of bias will be summarised across
domains (excluding domains of blinding of participants and per-
sonnel and excluding participant reported outcomes) using a clas-
sification of low risk (low risk of bias in all key domains), high
risk (high risk of bias in at least one key domain) and unclear risk
(unclear risk in at least one key domain). A ‘Summary of findings’
table will be created for the primary outcome of adherence and
will be rated in accordance with methods of the GRADE (Grading
of Recommendations Assessment, Development and Evaluation)
Working Group approach (Guyatt 2008).
When considering treatment effects, we will take into account the
risk of bias for the studies that contribute to that outcome.
Measures of treatment effect
All data will be entered and analysed in RevMan software (Review
Manager 2015). We will perform statistical analyses using the sta-
tistical software provided by Cochrane. For continuous variables,
we will calculate mean differences (MDs) or standardised mean
differences (SMDs) with 95% confidence intervals (CIs) and for
dichotomous variables we will present risk ratios (RRs) with 95%
CIs and number needed to treat for an additional beneficial out-
come (NNTB) (such as percentage above a threshold of number
of doses or
proportion starting DMT) or number needed to treat for an ad-
ditional harmful outcome (NNTH) (such as proportion stopping
medication). Where the same outcome measure is expressed as a
continuous variable in some studies and dichotomous in others,
we will initially analyse them separately, but we will also conduct
an additional analysis transforming the effect size estimates from
the latter to SMDs in order to facilitate a meta-analysis. Where
the same outcome variable is expressed in both continuous and
dichotomous forms within the same study, we will prioritise the
former.We will undertake meta-analysis only when the studies are
sufficiently homogeneous in terms of participants, interventions
and outcomes to provide a meaningful summary.
Unit of analysis issues
In the case of cluster-randomised trials to avoid unit of analysis
errors, we will adjust the results when the unit of analysis is pre-
sented as the total number of individual participants rather than
the number of clusters using the mean cluster size and the intra-
cluster correlation coefficient (ICC), (Higgins 2011b). If the ICC
is not available, we will impute it using estimates from other stud-
ies or general recommendations. If there is uncertainty about what
value to use, we will conduct a sensitivity analysis trying a variety
of plausible values. For cross-over trials we will use the pre-cross
over results only. For trials where there have been multiple treat-
ment attempts per participant, we will use participant (rather than
treatment attempt) as the unit of analysis. For trials withmore than
two arms (either multiple treatment arms or multiple comparator
arms), the Clinical Heterogeneity Group will consider which arms
can be combined into pair-wise comparisons or whether interven-
tion arms are dissimilar enough that they should be included in
separate meta-analyses. This will ensure that individual trial arms
are not included more than once in each meta-analysis.
Dealing with missing data
If trial level data are missing or inadequate, we will contact the
primary authors (by email, letter or telephone) to obtain additional
information or further clarification.
Assessment of heterogeneity
We will assess clinical and methodological heterogeneity by con-
sidering the characteristics of participants, interventions, study de-
signs and outcomes. We will attempt to blind this group to study
results.
For each set of clinically/methodologically homogenous studies,
we will examine statistical heterogeneity by visually inspecting
whether the CIs overlap on the forest plot, (if used, see below),
with poor overlap indicating the presence of heterogeneity), by
using the Chi2 statistic (significance level of 0.1) and using the I
2 statistic (Higgins 2011a). We will perform meta-analysis using
random-effects models where there is substantial statistical hetero-
geneity (I2 > 50%).
Assessment of reporting biases
If we are able to poolmore than 10 trials, wewill use funnel plots to
explore the possibility of publication bias. A comprehensive search
strategy, which includes searching for unpublished studies (grey
literature), and searching trials registers (see Search methods for
identification of studies) will be used tominimise reporting biases.
We will contact the authors for the full data or the reason for not
publishing the data, where data are not reported or published in
full.
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Data synthesis
We will present a narrative synthesis of the included studies de-
scribing major characteristics and results. If studies are sufficiently
similar in terms of participants, eligibility criteria, interventions
(type and intent) and outcomes (including the time frame of fol-
low-up), as determined by the Clinical Heterogeneity Group, we
will consider meta-analysis as described in the assessment of het-
erogeneity section. See section onMeasures of treatment effect for
details of analysis
Subgroup analysis and investigation of heterogeneity
Results from studies will only be pooled if blinded assessment of
clinical and methodological heterogeneity determines that they
are similar enough. If there are sufficient studies, it is anticipated
that the main analysis will consist of a series of meta-analyses on
subgroups of clinically and methodologically homogenous stud-
ies. However, we will also use meta-regression techniques to see
whether study level characteristics (such as type of intervention)
impact on effect size.
Sensitivity analysis
A sensitivity analysis will be conducted when one or more stud-
ies have a high risk of introducing bias (for example inadequate
data, withdrawals by more than 40% of the participants, nearly
total non-adherence to the protocol, or very poor or non-adjusted
comparability in the baseline criteria).
’Summary of findings’ table
Wewill present the overall quality of the evidence for each outcome
according with the methods of the GRADE (Grading of Recom-
mendations Assessment, Development and Evaluation) Working
Group (GRADE Working Group 2004) approach, which takes
into account five criteria not only related to internal validity (risk
of bias, inconsistency, imprecision, publication bias), but also to
external validity, such as directness of results (Guyatt 2008). For
each comparison, two review authors will independently rate the
quality of evidence for each outcome as ’high’, ’moderate’, ’low’,
or ’very low’ using (GRADEprofiler 2011). We will resolve any
discrepancies by consensus, or, if needed, by arbitration by a third
review author. For each comparison, we will present a summary of
the evidence for the main outcomes in a ’Summary of findings’ ta-
ble, which provides key information about the best estimate of the
magnitude of the effect in relative terms and absolute differences
for each relevant comparison of alternative management strate-
gies; numbers of participants and studies addressing each impor-
tant outcome; and the rating of the overall confidence in effect
estimates for each outcome (Guyatt 2008; Schünemann 2011). If
meta-analysis is not possible, we will present results in a narrative
’Summary of findings’ table.
We will create a ’Summary of findings’ table using the following
outcomes:
• adherence to treatment (DMTs);
• motivation to adhere;
• self-efficacy to adhere;
• healthcare engagement (e.g., attending a neurology
appointment to discuss re-initiation of DMTs).
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Appendix 1. Keywords
{Motivational Interviewing} OR {Behavior Therapy} OR {Behaviour Therapy} OR {transtheoretical model} OR {positive psychology
interventions} OR {Anger} OR {Art Therapy} OR {Attention} OR {Psychoanalytic Therapy} OR {Cognitive Therapy} OR {Personal
Construct Theory} OR {Counseling} OR {Crisis Intervention} OR {Psychotherapy} OR {Depression} OR {Family Therapy} OR
{Gestalt Theory} OR {Psychotherapy} OR {Hypnosis} OR {Milieu Therapy} OR {Nondirective Therapy} OR {Problem Solving} OR
{Psychoanalysis} OR {Psychodrama} OR {Play Therapy} OR {Self Concept} OR {Self Efficacy} OR {Self Assessment } OR {Social
Support} OR {Socio environmental Therapy} OR {psychological stress} OR {anger management} OR {anxiety} OR {art therapy} OR
{assertiveness} OR {attention} OR {aversion therapy} OR {biofeedback training} OR {brief therapy} OR {colour therapy}OR {cognitive
rehabilitation} OR {concentration} OR {construct theory} OR {counseling} OR {crisis intervention} OR {dance therapy} OR {emotion
focusing} OR {executive function} OR {expert patient} OR {exposure} OR {functional analysis} OR {milieu therapy} OR {mood } OR
{role play} OR {schema-focussed} OR {self control} OR {self-esteem}OR {self-efficacy}OR {self-image}OR {self management} OR {self
monitoring} OR {self talk} OR {self disclosure} OR {self narrative} OR {social support} OR {socio environmental} OR {sociotherapy}
OR {supportive therapy} OR {transactional} OR {systemic} OR {client-centred} OR {client-centered} OR {acceptance therapy} OR
{commitement therapy} OR {mindfulness-based cognitive therapy} OR {mindfulness-based stress reduction} OR {well-being therapy}
AND {medication adherence } OR {medication persistence} OR {compliance} OR {persistence} OR {adherence} OR {cooperation}
OR {compliance therapy} OR {patient education} OR {reminder systems} OR {decision support techniques} OR {decision making}
OR {computer assisted} AND {monoclonal antibodies} OR {immunosuppressive agents} OR {neuroprotective agents} OR {disease-
modifying therapy} OR {disease-modifying therapies} OR {DMTs}
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